摘要
目的 探讨瑞舒伐他汀钙对2型糖尿病（T2DM）伴骨质疏松症患者骨密度以及颈动脉硬化斑块的影响.方法 将82例T2DM伴骨质疏松症患者随机分成两组,观察组41例,对照组41例.对照组按照常规治疗方法,胰岛素、钙尔奇D治疗;观察组于对照组基础上给予瑞舒伐他汀钙10 mg,1次/d口服治疗.两组患者均治疗12周.治疗后比较其血糖水平、骨密度值、颈动脉硬化斑块变化情况.结果 治疗后观察组FBG水平（7.2±0.4） mmol/L、2 hBG（9.2±0.6） mmol/L、HbAlc（7.2±0.4）%均较治疗前（9.6±0.5） mmol/L、（12.3±0.6） mmol/L、（9.8±0.7）%降低,差异有统计学意义（t值分别为24.0、23.39、20.65,P均〈0.05）;对照组FBG（8.4±0.3） mmol/L、2 hBG（10.5±0.6） mmol/L、HbAlc（8.3±0.6）%均较治疗前（9.3±0.3） mmol/L、（12.0±0.8） mmol/L、（9.9±0.5）%降低,差异有统计学意义（t值分别为13.58、9.60、13.12,P均〈0.05）;且观察组上述3个指标均低于对照组（t值分别为-15.37、-9.81、-9.77,P均〈0.05）.观察组治疗1疗程后可见患者股骨颈骨密度值（0.699±0.111） g/cm2较治疗前（0.665±0.106） g/cm2增加,治疗前后比较差异有统计学意义 （t=0.790,P〈0.05）;对照组治疗后骨密度值（0.669±0.130） g/cm2较治疗前（0.662±0.119） g/cm2无明显改变 （t=-0.25, P〉0.05）;且治疗后观察组股骨颈骨密度值高于对照组（t=0.842,P〈0.05）.观察组治疗1疗程后可见患者颈动脉内膜-中膜厚度（IMT） （1.202±0.18） mm和斑块积分（3.62±0.33）分较治疗前（1.582±0.369） mm、（4.39±0.37）分降低,治疗前后比较差异有统计学意义 （t值分别为0.778、9.945,P均〈0.05） ,对照组治疗后IMT （1.487±0.345） mm和斑块积分（4.16±0.26）分较治疗前（1.499±0.356） mm和斑块积分（4.28±0.28）分无明显改变（t值分别为0.155,2.011,P均〉0.05）;但观察组与对照组比较差异有统计学意义（t值分别为0.534,0.
Objective To investigate the effects of rosuvastatin calcium on bone mineral density and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus complicated with osteoporosis.Methods Eighty-two T2DM patients with osteoporosis were randomly divided into two groups,41 cases in the treatment group and 41 cases in the control group.The control group received routine treatment,including insulin and Caltrate D treatment.The observation group was treated with rosuvastatin calcium 10 mg 1 time/d orally,on the basis of the routine treatmentv.The two groups were treated for 12 weeks.After treatment,the blood glucose level,bone mineral density and carotid atherosclerotic plaques were compared.Results After treatment,the levels of blood sugar,FBG （（7.2±0.4） mmol/L）,2 hBG （（9.2±0.6） mmol/L）,HbAlc （（7.2±0.4） mmol/L） in the observation groups were lower than those before treatment （（9.6±0.5） mmol/L,（12.3±0.6） mmol/L,（9.8±0.7） mmol/L,t=24.0,23.39,20.65,P〈0.05）,the levels of blood sugar,FBG,2 hBG,HbAlc in the control group were （8.4±0.3） mmol/L,（10.5±0.6） mmol/L and （8.3±0.6） mmol/L,lower than those before treatment （（9.3±0.3） mmol/L,（12.0±0.8） mmol/L,（9.9±0.5） mmol/L,t=13.58,9.60,13.12,P〈0.05）.The three indexes in the observation group were lower than those in the control group （t=-15.37,-9.8,-9.77,P〈0.05）.After 1 course of treatment,the femoral neck BMD value in the observation group was higher than that before treatment （（0.699±0.111） g/cm2 vs.（0.665±0.106） g/cm2,t=0.790,P〈0.05）,there was no significant increase in the BMD value in the control group after treatment （（0.669±0.130） g/cm2 vs.（0.662±0.119） g/cm2,t=-0.25,P〉0.05）,the BMD of femoral neck in the observation group after treatment was higher than that in the control group （t=0.842,P〈0.05）.After 1 course of treatment,IMT value and plaque score in the observation group were lower than those before treatment （（1.202±0.18） m
作者
韦建
Wei Jian(Endocrinology Department, Dafeng People ＇s Hospital of Yancheng , Yancheng 224100, China)
出处
《中国综合临床》
2017年第8期705-709,共5页
Clinical Medicine of China
关键词
瑞舒伐他汀钙
2型糖尿病
骨质疏松
骨密度
颈动脉硬化斑块
Rosuvastatin calcium
Type 2 diabetes mellitus
Osteoporosis
Bone mineral density
Adiponectin
Carotid atherosclerotic plaques
